FDA unveils strategy to enhance safety in infant formula supply chain

USA – The US Food and Drug Administration (FDA) has announced plans to enhance oversight of infant formula production, continuing its efforts to secure a reliable and resilient supply chain. 

This initiative follows the February 2022 product recall and subsequent shortage, which stemmed from a salmonella outbreak at Abbott Industries’ Michigan factory. 

The recall led to a factory shutdown, prompting the US government to invoke emergency measures to import supplies. The crisis also sparked a comprehensive review of the FDA’s operations.

A report by the FDA outlines a long-term strategy to improve the resilience of the US infant formula market, building on the Immediate National Strategy introduced in early 2023. 

According to the FDA, this new approach emphasizes actions to prevent contamination and safeguard the integrity of the supply chain. 

Collaborative efforts with other government agencies are also central to the plan, as the FDA stated that no single agency can fully address the vulnerabilities in the infant formula market.

The strategy includes measures to encourage new market entrants, foster collaboration, and enhance information sharing among stakeholders. 

The FDA reported that it is seeking additional tools and regulatory authority to strengthen its oversight. 

FDA Deputy Commissioner for Human Foods, Jim Jones, noted that while progress has been made in protecting the supply chain, further actions are necessary to ensure its integrity and resilience.

The FDA plans to conduct annual food safety inspections and sampling of all infant formula manufacturers to enhance safety and compliance. 

It will also establish yearly targets for microbiological and nutritional analysis of products from foreign manufacturers. 

To mitigate potential shortages, the FDA aims to prioritize the review of premarket submissions for new infant formula products and address redundancy risks, particularly for specialty formulas.

According to the FDA, international harmonization of regulatory requirements is being explored to provide flexibility in managing potential supply disruptions. 

Additionally, the agency seeks to strengthen collaboration with the US Department of Agriculture (USDA) to support resilience and reserve planning. 

The FDA will also maintain communication with the Council of State and Territorial Epidemiologists as Cronobacter, a bacteria linked to infant formula contamination, is now classified as a nationally notifiable disease.

Efforts to improve information sharing with major producers and retailers are also underway, with plans to host webinars and maintain regular contact with manufacturers. 

The FDA stated that it will continue developing educational materials for consumers and medical professionals in collaboration with the Department of Health and Human Services (HHS). 

It also intends to publish guidance documents to promote market diversification and update regulations to reflect the latest scientific advancements.

In pursuit of a robust infant formula supply chain, the FDA plans to work with Congress to advance legislative proposals aimed at strengthening regulatory oversight and ensuring the safety and availability of infant formula in the US.